MedTrace Logo

Efficacy and Safety of iStent Inject and Inject W in the Management of Primary Open-angle Glaucoma

NCT05062668 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-02-08

No results posted yet for this study

Summary

Primary open-angle glaucoma (POAG) is a chronic eye disease in which the only validated treatment is to lower intraocular pressure (IOP). It is the 2nd leading cause of blindness worldwide. The iStent® inject and inject W is an implantable device that is part of a new entity of so-called minimally invasive glaucoma surgery whose goal is to lower IOP with minimal tissue disruption in order to avoid the complications of conventional glaucoma surgery. This surgery is used in conjunction with cataract surgery in France. The primary objective is to study the 1-year efficacy and safety of combined cataract and iStent inject and inject W in the management of POAG in an observational, retrospective, controlled study of a cohort of POAG patients undergoing cataract surgery only.

Conditions

  • POAG
  • MIGS

Interventions

PROCEDURE

cataract operation and istent

a cataract operation and the placement of one or two iStent inject or inject W at the same time

PROCEDURE

cataract operation only

Patients have a classic postoperative treatment after cataract.

Sponsors & Collaborators

  • Central Hospital Saint Quentin

    collaborator OTHER_GOV

  • Centre Hospitalier Universitaire, Amiens

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-08
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05062668 on ClinicalTrials.gov